Corpus Intelligence IC Memo — BANNER ESTRELLA MEDICAL CENTER 2026-04-26 02:13 UTC
IC Memo — BANNER ESTRELLA MEDICAL CENTER
Investment Committee Memorandum | AZ | 317 beds | Grade B | EBITDA uplift $135.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

BANNER ESTRELLA MEDICAL CENTER

CCN 030115 | nan, AZ | 317 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

BANNER ESTRELLA MEDICAL CENTER is a 317-bed large academic medical center in nan, AZ with $1.84B in net patient revenue and a 79.2% operating margin. The hospital serves a payer mix of 12.6% Medicare, 39.8% Medicaid, and 47.6% commercial.

Thesis: Platform Growth. Our ML models identify $135.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 79.2% to 86.5% (+736bps).

Net Revenue HCRIS$1.84B
Current EBITDA COMPUTED$1.45B
Operating Margin COMPUTED79.2%
Occupancy HCRIS72.5%
Revenue / Bed COMPUTED$5.8M
Net-to-Gross HCRIS100.0%
Distress Probability ML52.9%

2. Market Context & Competitive Position

124
AZ Hospitals
-0.8%
State Median Margin
30
Comparable Hospitals

AZ has 124 Medicare-certified hospitals with a median operating margin of -0.8%. The target's margin of 79.2% places it above the state median. Among 30 size-comparable peers (158-634 beds), the median margin is -0.8%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (158-634), prioritizing same-state peers. 30 hospitals in the comp set.

HospitalStateBedsRevenueMargin
BANNER ESTRELLA MEDICAL CENTER (Target)AZ317$1.84B79.2%
MAYO CLINIC HOSPITALAZ315$2.25B1.4%
BANNER BAYWOOD MEDICAL CENTERAZ323$1.39B79.1%
ST. JOSEPHS HOSPITAL & MEDICALAZ515$1.31B-17.7%
PHOENIX CHILDRENS HOSPITALAZ352$1.26B6.0%
BANNER UNIVERSITY MED CENTER TAZ533$1.03B-4.6%
BANNER DESERT MEDICAL CENTERAZ629$833.1M12.6%
TUCSON MEDICAL CENTERAZ499$747.4M-2.8%
CHANDLER REGIONAL MEDICAL CENTAZ429$700.3M-2.0%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $135.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$38.6M+210bp18mo
Cost to Collect4.5%2.5%$36.7M+200bp12mo
Denial Rate Reduction12.0%6.5%$36.4M+198bp12mo
A/R Days Reduction5200.0%3800.0%$22.4M+122bp9mo
Clean Claim Rate88.0%96.0%$1.2M+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$38.6M
Cost to Collect
$36.7M
Denial Rate Reduction
$36.4M
A/R Days Reduction
$22.4M
Clean Claim Rate
$1.2M
Total EBITDA Uplift$135.2M
Current EBITDA$1.45B
+ RCM Uplift+$135.2M
Pro Forma EBITDA$1.59B
Current Margin79.2%
Pro Forma Margin86.5%
WC Released (1x)$70.5M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$2.24B$10.95B4.89x37.4%
Base (11x exit)10.0x11.0x$2.24B$12.77B5.71x41.7%
Bull Case9.0x11.0x$2.01B$13.94B6.92x47.2%
Bull (12x exit)9.0x12.0x$2.01B$15.80B7.85x51.0%
Bear Case11.0x10.0x$2.46B$9.54B3.88x31.1%
Bear (11x exit)11.0x11.0x$2.46B$11.30B4.59x35.6%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumElevated Medicaid exposure (39.8%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
HighElevated distress probabilityModel estimates 52.9% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 30 hospitals with 158-634 beds
  • Same-state prioritization (n=31)
  • Comp margins: P25=-3.8% / P50=-0.8% / P75=6.3%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.